LumibirdHAM:QTL -3.93%65 PEG Ratio is 2.52 as of Jun. 25, 2026, which is 2% above its 10-year median of 2.47. GuruFocus rates HAM:QTL with a GF Score™ of 65/100 and a GF Value™ of €16.31 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 36 Medical Diagnostics & Research companies, Lumibird ranks worse than 55.56% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Lumibird's PE Ratio without NRI is 32.98. Lumibird's 5-Year EBITDA growth rate is 13.10%. Therefore, Lumibird's PEG Ratio for today is 2.52.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Lumibird's PEG Ratio or its related term are showing as below:
HAM:QTL'
s PEG Ratio Range Over the Past 10 Years
Min: 0.46 Med: 2.47 Max: 8.17
Current: 2.77
During the past 13 years, Lumibird's highest PEG Ratio was 8.17. The lowest was 0.46. And the median was 2.47.
HAM:QTL's PEG Ratio is ranked worse than 55.56% of 36
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.2
vs HAM:QTL: 2.77
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Lumibird (HAM:QTL) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Lumibird PEG Ratio Related Terms
Lumibird PEG Ratio Historical Data
* Premium members only.
The historical data trend for Lumibird's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Lumibird's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumibird PEG Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lumibird's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Lumibird's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Lumibird (HAM:QTL) has a PEG Ratio of 2.52 as of Jun. 25, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Lumibird and its competitors. This is near median its historical median of 2.47. Over the past decade, Lumibird's PEG Ratio has ranged from 0.46 to 8.17. According to the industry distribution chart, Lumibird ranks #20 out of 36 companies in the Medical Diagnostics & Research industry, placing it in the top 55.6%.
Is Lumibird's PEG Ratio too high?
Lumibird's current PEG Ratio of 2.52 is near median its 10-year median of 2.47. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 8.17. The Medical Diagnostics & Research industry median PEG Ratio is 2.20. Lumibird's value of 2.52 is 14.5% above this industry median. Based on the distribution chart, Lumibird ranks #20 out of 36 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lumibird has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumibird's PEG Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumibird ranks #20 out of 36 companies for PEG Ratio. This places Lumibird in the lower half of its industry. The industry median PEG Ratio is 2.20. Lumibird's value of 2.52 is 14.5% above this benchmark. Historically, Lumibird's own PEG Ratio has ranged from 0.46 to 8.17 over the past decade. While the company's 10-year median is 2.47 vs. the industry median of 2.20, Lumibird has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Diagnostics & Research company?
The median PEG Ratio among Medical Diagnostics & Research companies is 2.20, based on 36 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumibird's current PEG Ratio of 2.52 is 14.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Lumibird and its competitors. For the Medical Diagnostics & Research industry, the median PEG Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumibird's current PEG Ratio is 2.52, which is near median its own 10-year median of 2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumibird stock overvalued right now?
Based on GuruFocus' analysis, Lumibird (HAM:QTL) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.31, compared to a current price of €23.25 — trading 42.6% above its estimated fair value. The current PEG Ratio is 2.52, which is near median its 10-year median of 2.47 and 14.5% above the Medical Diagnostics & Research industry median of 2.20. Lumibird's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Lumibird (HAM:QTL), the current PEG Ratio is 2.52 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumibird (HAM:QTL) Overvalued in 2026?
Based on GuruFocus' analysis, Lumibird stock appears to be overvalued.
The current stock price of €23.25 is trading 42.6% above its estimated GF Value™ of €16.31.
GuruFocus considers Lumibird to be Significantly Overvalued.
Key valuation signals for HAM:QTL:
PEG Ratio: 2.52 (near median its 10-year median of 2.47)
GF Value™: €16.31 vs. price of €23.25 (42.6% above fair value)
Industry Position: 14.5% above the Medical Diagnostics & Research median (#20 of 36)
No single metric tells the full story. See the HAM:QTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
65GF Score
Get the complete analysis for HAM:QTL
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:QTL has been successfully added to your 
